Ruboxistaurin HCl

Overview

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-maximal inhibitory constant of 4.5 and 5.9 nM, respectively. The half-life of ruboxistaurin, which can be orally administered, is approximately 9h and that of its metabolite 16h, therefore allowing once-daily dosing. Based on data from clinicalTrials.gov, Children's Hospital Medical Center, Cincinnati plan a phase I/II trial of the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure on June 9, 2016.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Neurological Disease | PKC

Product Information

• Catalog No.: B0084-263880
• CAS No.: 169939-93-9
• Molecular Formula: C28H28N4O3.HCl
• Molecular Weight: 505.01
• Purity: > 95%
• Storage: Store in a cool and dry place and at 0 - 4°C for short term (days to weeks) or -42°C for long term (months to years).
• Solubility: Soluble to 20 mM in DMSO

Source

Original product source